| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rhinitis, Allergic | 33 | 2021 | 704 | 8.52 | Why? |
| Asthma | 53 | 2021 | 4383 | 5.29 | Why? |
| Rhinitis | 19 | 2021 | 626 | 3.63 | Why? |
| Picea | 8 | 2018 | 8 | 3.09 | Why? |
| Hypersensitivity | 18 | 2021 | 1137 | 2.39 | Why? |
| Brassica | 3 | 2021 | 66 | 1.95 | Why? |
| Mobile Applications | 12 | 2021 | 3032 | 1.84 | Why? |
| Rhinitis, Allergic, Seasonal | 6 | 2019 | 121 | 1.74 | Why? |
| Allergens | 14 | 2021 | 728 | 1.68 | Why? |
| TRPA1 Cation Channel | 2 | 2021 | 82 | 1.68 | Why? |
| Antigens, Plant | 3 | 2019 | 40 | 1.65 | Why? |
| NF-E2-Related Factor 2 | 3 | 2021 | 373 | 1.47 | Why? |
| Fluticasone | 2 | 2018 | 65 | 1.38 | Why? |
| Rhinitis, Allergic, Perennial | 3 | 2018 | 36 | 1.32 | Why? |
| Work Performance | 3 | 2017 | 186 | 1.32 | Why? |
| Immunoglobulin E | 11 | 2020 | 557 | 1.21 | Why? |
| Sinusitis | 9 | 2021 | 649 | 1.19 | Why? |
| Desensitization, Immunologic | 9 | 2021 | 574 | 1.04 | Why? |
| Fermentation | 2 | 2020 | 156 | 1.02 | Why? |
| Decision Support Systems, Clinical | 2 | 2019 | 551 | 1.01 | Why? |
| Smartphone | 6 | 2019 | 1840 | 0.95 | Why? |
| Multimorbidity | 5 | 2019 | 703 | 0.88 | Why? |
| Vegetables | 2 | 2020 | 340 | 0.87 | Why? |
| Enterotoxins | 2 | 2019 | 115 | 0.84 | Why? |
| TRPV Cation Channels | 1 | 2021 | 88 | 0.82 | Why? |
| Omalizumab | 2 | 2019 | 158 | 0.80 | Why? |
| Spices | 1 | 2020 | 130 | 0.79 | Why? |
| Anaphylaxis | 4 | 2021 | 940 | 0.78 | Why? |
| Cell Phone | 2 | 2017 | 750 | 0.77 | Why? |
| Allergists | 3 | 2021 | 266 | 0.75 | Why? |
| Phthalazines | 1 | 2018 | 26 | 0.72 | Why? |
| Immunization | 7 | 2021 | 2019 | 0.72 | Why? |
| Communications Media | 1 | 2020 | 151 | 0.71 | Why? |
| Salmeterol Xinafoate | 1 | 2017 | 28 | 0.70 | Why? |
| Wood | 1 | 2017 | 29 | 0.69 | Why? |
| Efficiency | 3 | 2019 | 420 | 0.69 | Why? |
| Breeding | 1 | 2017 | 60 | 0.69 | Why? |
| Exome | 1 | 2018 | 207 | 0.68 | Why? |
| Skilled Nursing Facilities | 3 | 2020 | 1098 | 0.68 | Why? |
| Genome, Plant | 1 | 2017 | 41 | 0.67 | Why? |
| Plant Extracts | 2 | 2019 | 1514 | 0.66 | Why? |
| Delivery of Health Care, Integrated | 3 | 2017 | 1549 | 0.65 | Why? |
| Rain | 1 | 2017 | 108 | 0.65 | Why? |
| Loratadine | 2 | 2018 | 18 | 0.62 | Why? |
| Internet | 3 | 2019 | 6204 | 0.60 | Why? |
| DNA, Plant | 4 | 2018 | 14 | 0.59 | Why? |
| Computer Security | 1 | 2019 | 408 | 0.58 | Why? |
| Visual Analog Scale | 4 | 2019 | 151 | 0.55 | Why? |
| Antigens, Bacterial | 1 | 2017 | 330 | 0.54 | Why? |
| Adrenal Cortex Hormones | 7 | 2021 | 6537 | 0.49 | Why? |
| Medication Adherence | 3 | 2018 | 1270 | 0.48 | Why? |
| DNA Methylation | 4 | 2018 | 688 | 0.48 | Why? |
| Polymorphism, Single Nucleotide | 5 | 2018 | 3607 | 0.46 | Why? |
| Humans | 132 | 2021 | 930598 | 0.46 | Why? |
| Long-Term Care | 2 | 2020 | 2047 | 0.45 | Why? |
| Bronchodilator Agents | 1 | 2017 | 444 | 0.45 | Why? |
| Staphylococcus aureus | 2 | 2019 | 844 | 0.44 | Why? |
| Accidental Falls | 3 | 2021 | 448 | 0.44 | Why? |
| Diet | 2 | 2020 | 2052 | 0.44 | Why? |
| Genomics | 3 | 2019 | 3118 | 0.44 | Why? |
| Phenotype | 10 | 2019 | 4037 | 0.43 | Why? |
| Histamine H1 Antagonists, Non-Sedating | 1 | 2010 | 33 | 0.43 | Why? |
| Europe | 15 | 2020 | 12702 | 0.41 | Why? |
| Biological Products | 4 | 2021 | 2331 | 0.40 | Why? |
| Taste Disorders | 1 | 2021 | 1720 | 0.39 | Why? |
| Nursing Homes | 3 | 2021 | 4155 | 0.38 | Why? |
| Cross Reactions | 2 | 2018 | 4374 | 0.37 | Why? |
| Epigenesis, Genetic | 4 | 2018 | 711 | 0.35 | Why? |
| Histamine H1 Antagonists | 2 | 2019 | 79 | 0.35 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.35 | Why? |
| Critical Pathways | 1 | 2017 | 1587 | 0.33 | Why? |
| Chromosome Mapping | 2 | 2017 | 178 | 0.33 | Why? |
| Nasal Obstruction | 2 | 2018 | 131 | 0.33 | Why? |
| Respiratory Tract Diseases | 1 | 2015 | 1061 | 0.33 | Why? |
| Pollen | 2 | 2018 | 137 | 0.33 | Why? |
| Anti-Asthmatic Agents | 4 | 2019 | 427 | 0.32 | Why? |
| Antioxidants | 3 | 2021 | 1593 | 0.32 | Why? |
| Administration, Intranasal | 3 | 2020 | 1132 | 0.31 | Why? |
| Food Hypersensitivity | 4 | 2019 | 397 | 0.31 | Why? |
| Anti-Allergic Agents | 2 | 2019 | 167 | 0.31 | Why? |
| Quality of Life | 9 | 2019 | 9820 | 0.30 | Why? |
| Home Care Services | 1 | 2017 | 1351 | 0.29 | Why? |
| Pilot Projects | 4 | 2018 | 5182 | 0.29 | Why? |
| Plant Proteins | 2 | 2018 | 194 | 0.29 | Why? |
| Vaccines | 2 | 2021 | 3692 | 0.29 | Why? |
| Conjunctivitis | 3 | 2018 | 318 | 0.29 | Why? |
| Telemedicine | 5 | 2021 | 25032 | 0.29 | Why? |
| Population Surveillance | 4 | 2017 | 4967 | 0.28 | Why? |
| Genetics, Population | 1 | 2004 | 162 | 0.27 | Why? |
| Respiratory Hypersensitivity | 1 | 2005 | 103 | 0.27 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.26 | Why? |
| Surveys and Questionnaires | 11 | 2018 | 43792 | 0.26 | Why? |
| Search Engine | 2 | 2020 | 628 | 0.24 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.24 | Why? |
| Chronic Disease | 10 | 2021 | 5139 | 0.24 | Why? |
| CpG Islands | 3 | 2018 | 230 | 0.24 | Why? |
| Utilization Review | 1 | 2021 | 81 | 0.23 | Why? |
| Nasal Polyps | 3 | 2021 | 221 | 0.23 | Why? |
| Smoking | 5 | 2020 | 3358 | 0.22 | Why? |
| Lactobacillales | 1 | 2020 | 20 | 0.22 | Why? |
| Climate | 2 | 2018 | 557 | 0.22 | Why? |
| Helsinki Declaration | 1 | 2020 | 26 | 0.22 | Why? |
| Male | 38 | 2021 | 367725 | 0.22 | Why? |
| Female | 45 | 2021 | 380317 | 0.22 | Why? |
| Rare Diseases | 1 | 2005 | 373 | 0.22 | Why? |
| User-Computer Interface | 2 | 2018 | 1068 | 0.21 | Why? |
| Genetic Linkage | 2 | 2017 | 87 | 0.21 | Why? |
| Environment | 2 | 2020 | 769 | 0.21 | Why? |
| Pulmonary Emphysema | 1 | 2002 | 122 | 0.21 | Why? |
| Bronchitis | 1 | 2002 | 146 | 0.21 | Why? |
| Anorexia | 1 | 2021 | 194 | 0.21 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.20 | Why? |
| Nasal Mucosa | 2 | 2018 | 1218 | 0.20 | Why? |
| Sublingual Immunotherapy | 1 | 2020 | 88 | 0.20 | Why? |
| Receptors, Interleukin-5 | 1 | 2019 | 6 | 0.20 | Why? |
| Contig Mapping | 1 | 2018 | 5 | 0.20 | Why? |
| Disease Management | 4 | 2018 | 6841 | 0.20 | Why? |
| Acetophenones | 1 | 2018 | 7 | 0.20 | Why? |
| Psychometrics | 2 | 2017 | 1269 | 0.20 | Why? |
| Molecular Sequence Annotation | 2 | 2018 | 478 | 0.20 | Why? |
| Ecology | 1 | 2020 | 140 | 0.20 | Why? |
| Moths | 1 | 2018 | 24 | 0.19 | Why? |
| Artemisia | 1 | 2019 | 27 | 0.19 | Why? |
| Epinephrine | 1 | 2021 | 323 | 0.19 | Why? |
| B-Lymphocytes, Regulatory | 1 | 2018 | 24 | 0.19 | Why? |
| Interleukin-4 Receptor alpha Subunit | 1 | 2019 | 46 | 0.19 | Why? |
| Pinaceae | 1 | 2018 | 1 | 0.19 | Why? |
| Atmosphere Exposure Chambers | 1 | 2018 | 2 | 0.19 | Why? |
| Ambrosia | 1 | 2018 | 4 | 0.19 | Why? |
| Interleukin-5 | 1 | 2019 | 138 | 0.19 | Why? |
| Ukraine | 1 | 2019 | 137 | 0.19 | Why? |
| Cell Respiration | 1 | 2018 | 26 | 0.19 | Why? |
| Photosynthesis | 1 | 2018 | 38 | 0.18 | Why? |
| Research Design | 4 | 2019 | 5830 | 0.18 | Why? |
| Odds Ratio | 4 | 2018 | 5861 | 0.18 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.18 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2018 | 92 | 0.18 | Why? |
| Gene Expression Regulation, Plant | 1 | 2018 | 110 | 0.17 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.17 | Why? |
| Acclimatization | 1 | 2018 | 69 | 0.17 | Why? |
| Synteny | 1 | 2017 | 38 | 0.17 | Why? |
| Prevalence | 9 | 2020 | 25773 | 0.17 | Why? |
| Chitinase-3-Like Protein 1 | 1 | 2017 | 28 | 0.17 | Why? |
| Walking Speed | 1 | 2018 | 77 | 0.17 | Why? |
| Gene Dosage | 1 | 2017 | 101 | 0.17 | Why? |
| Trees | 1 | 1997 | 25 | 0.17 | Why? |
| Antigens, Dermatophagoides | 1 | 2017 | 25 | 0.17 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 9335 | 0.17 | Why? |
| Adult | 28 | 2020 | 244371 | 0.17 | Why? |
| Plant Leaves | 1 | 2018 | 233 | 0.17 | Why? |
| Quality Control | 1 | 2021 | 628 | 0.17 | Why? |
| Pyroglyphidae | 1 | 2017 | 52 | 0.17 | Why? |
| Patient Advocacy | 1 | 2019 | 173 | 0.17 | Why? |
| Histamine Antagonists | 1 | 2019 | 203 | 0.17 | Why? |
| Eosinophils | 3 | 2020 | 848 | 0.17 | Why? |
| DNA, Ribosomal | 1 | 1997 | 112 | 0.17 | Why? |
| Hypersensitivity, Immediate | 1 | 2019 | 134 | 0.17 | Why? |
| Presenteeism | 1 | 2017 | 63 | 0.17 | Why? |
| Portugal | 3 | 2018 | 1265 | 0.17 | Why? |
| Postural Balance | 1 | 2018 | 144 | 0.17 | Why? |
| Longitudinal Studies | 3 | 2021 | 9893 | 0.16 | Why? |
| Prenatal Exposure Delayed Effects | 2 | 2018 | 319 | 0.16 | Why? |
| Interleukin-4 | 1 | 1998 | 367 | 0.16 | Why? |
| Multigene Family | 1 | 2018 | 377 | 0.16 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.16 | Why? |
| Global Warming | 1 | 2018 | 93 | 0.16 | Why? |
| Turkey | 2 | 2018 | 3937 | 0.16 | Why? |
| Injections, Subcutaneous | 1 | 2019 | 647 | 0.16 | Why? |
| Web Browser | 1 | 2017 | 84 | 0.16 | Why? |
| Child | 19 | 2020 | 70012 | 0.16 | Why? |
| Kuwait | 1 | 2017 | 306 | 0.16 | Why? |
| Population Groups | 1 | 2018 | 212 | 0.15 | Why? |
| France | 5 | 2019 | 12074 | 0.15 | Why? |
| Retirement | 1 | 2017 | 157 | 0.15 | Why? |
| Physical Endurance | 1 | 2017 | 107 | 0.15 | Why? |
| Peanut Hypersensitivity | 1 | 2017 | 73 | 0.15 | Why? |
| Epigenomics | 1 | 2017 | 139 | 0.15 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.15 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.15 | Why? |
| Sequence Analysis, DNA | 3 | 2019 | 2830 | 0.15 | Why? |
| Seasons | 2 | 2019 | 4071 | 0.15 | Why? |
| Public Health Surveillance | 3 | 2018 | 3129 | 0.15 | Why? |
| Absenteeism | 1 | 2017 | 287 | 0.15 | Why? |
| Evidence-Based Practice | 2 | 2018 | 693 | 0.15 | Why? |
| Polypharmacy | 1 | 2018 | 347 | 0.14 | Why? |
| Common Cold | 1 | 2021 | 645 | 0.14 | Why? |
| Mucous Membrane | 1 | 2017 | 305 | 0.14 | Why? |
| Clinical Decision-Making | 3 | 2017 | 3755 | 0.14 | Why? |
| Administration, Inhalation | 1 | 2021 | 1647 | 0.14 | Why? |
| Healthy Aging | 1 | 2017 | 147 | 0.14 | Why? |
| Tandem Mass Spectrometry | 1 | 2021 | 1031 | 0.14 | Why? |
| Publishing | 1 | 2005 | 990 | 0.14 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.14 | Why? |
| Respiratory Function Tests | 2 | 2017 | 1755 | 0.14 | Why? |
| Models, Genetic | 1 | 2017 | 434 | 0.14 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.14 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.14 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.14 | Why? |
| Medical Records | 1 | 2017 | 513 | 0.14 | Why? |
| Vehicle Emissions | 1 | 2017 | 328 | 0.14 | Why? |
| Aged | 18 | 2021 | 215776 | 0.14 | Why? |
| Adolescent | 15 | 2019 | 86841 | 0.14 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.13 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.13 | Why? |
| Lipoproteins, LDL | 1 | 2014 | 115 | 0.13 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.13 | Why? |
| Genetic Variation | 3 | 2017 | 3919 | 0.13 | Why? |
| World Health Organization | 2 | 2017 | 4213 | 0.13 | Why? |
| Periodicals as Topic | 2 | 2017 | 1492 | 0.13 | Why? |
| Practice Guidelines as Topic | 5 | 2020 | 15421 | 0.13 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.13 | Why? |
| Nitrogen Dioxide | 1 | 2017 | 488 | 0.13 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.13 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.13 | Why? |
| Glycoproteins | 1 | 1998 | 615 | 0.13 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 3832 | 0.13 | Why? |
| Self Care | 2 | 2019 | 918 | 0.13 | Why? |
| Genome-Wide Association Study | 5 | 2018 | 1648 | 0.13 | Why? |
| Internationality | 2 | 2017 | 3297 | 0.13 | Why? |
| Self-Management | 1 | 2019 | 546 | 0.13 | Why? |
| Argentina | 1 | 2017 | 1141 | 0.12 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.12 | Why? |
| Skin Tests | 3 | 2019 | 229 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Bronchiolitis | 1 | 2017 | 297 | 0.12 | Why? |
| Child Development | 1 | 2017 | 352 | 0.12 | Why? |
| Middle Aged | 22 | 2019 | 270681 | 0.12 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.12 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.12 | Why? |
| Drug Hypersensitivity | 1 | 2018 | 401 | 0.12 | Why? |
| Respiration Disorders | 1 | 2018 | 526 | 0.12 | Why? |
| Bronchi | 3 | 1994 | 1048 | 0.12 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.12 | Why? |
| Walking | 1 | 2017 | 442 | 0.12 | Why? |
| Congresses as Topic | 3 | 2018 | 1347 | 0.12 | Why? |
| Health Plan Implementation | 1 | 2017 | 571 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Young Adult | 10 | 2019 | 93724 | 0.11 | Why? |
| Academies and Institutes | 3 | 2020 | 539 | 0.11 | Why? |
| Patient Participation | 1 | 2018 | 829 | 0.11 | Why? |
| Sweden | 1 | 2018 | 1969 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Geriatrics | 1 | 2020 | 947 | 0.11 | Why? |
| Cost of Illness | 1 | 2001 | 1903 | 0.11 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.10 | Why? |
| Frail Elderly | 2 | 2017 | 1427 | 0.10 | Why? |
| New Zealand | 1 | 2017 | 2073 | 0.10 | Why? |
| Precision Medicine | 2 | 2017 | 1477 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.10 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.10 | Why? |
| DNA, Viral | 1 | 2020 | 2521 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Software | 2 | 2019 | 2501 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.09 | Why? |
| Age Factors | 5 | 2017 | 21039 | 0.09 | Why? |
| Canada | 2 | 2017 | 6018 | 0.09 | Why? |
| Cross-Sectional Studies | 6 | 2019 | 53120 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.09 | Why? |
| Comorbidity | 6 | 2018 | 34796 | 0.09 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.09 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.09 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.09 | Why? |
| Genetic Predisposition to Disease | 3 | 2018 | 4027 | 0.09 | Why? |
| Gene Expression Regulation | 2 | 2018 | 4020 | 0.09 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.09 | Why? |
| Monitoring, Physiologic | 1 | 2019 | 1956 | 0.09 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.09 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.09 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3633 | 0.09 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.08 | Why? |
| Australia | 2 | 2019 | 6306 | 0.08 | Why? |
| Eye Diseases | 1 | 2018 | 1150 | 0.08 | Why? |
| Otolaryngology | 2 | 2018 | 1917 | 0.08 | Why? |
| Prospective Studies | 5 | 2018 | 43301 | 0.08 | Why? |
| Consensus | 2 | 2021 | 6345 | 0.08 | Why? |
| Evolution, Molecular | 2 | 2018 | 3691 | 0.08 | Why? |
| Research | 2 | 2017 | 2115 | 0.08 | Why? |
| Endoscopy | 1 | 2018 | 1564 | 0.08 | Why? |
| Gastrointestinal Microbiome | 1 | 2020 | 1961 | 0.08 | Why? |
| Pain Measurement | 1 | 2010 | 533 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.08 | Why? |
| Symptom Assessment | 2 | 2019 | 4967 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| Societies, Medical | 2 | 2018 | 6907 | 0.08 | Why? |
| DNA Primers | 2 | 2004 | 1170 | 0.08 | Why? |
| Signal Transduction | 2 | 2020 | 7207 | 0.08 | Why? |
| Guideline Adherence | 1 | 2019 | 2309 | 0.08 | Why? |
| Developing Countries | 1 | 2001 | 4283 | 0.07 | Why? |
| Administration, Sublingual | 1 | 2005 | 41 | 0.07 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.07 | Why? |
| Air Pollution | 3 | 2020 | 3504 | 0.07 | Why? |
| Attitude of Health Personnel | 1 | 2003 | 4741 | 0.07 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.07 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.07 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.07 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.07 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.07 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 116 | 0.07 | Why? |
| Urticaria | 1 | 2010 | 472 | 0.07 | Why? |
| Adrenergic beta-Agonists | 1 | 2004 | 93 | 0.07 | Why? |
| Honey | 1 | 1984 | 21 | 0.07 | Why? |
| Students, Medical | 1 | 2003 | 4032 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Child, Preschool | 9 | 2019 | 36283 | 0.07 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.06 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.06 | Why? |
| United States | 3 | 2021 | 46150 | 0.06 | Why? |
| Senegal | 1 | 2003 | 283 | 0.06 | Why? |
| DNA, Mitochondrial | 1 | 2004 | 163 | 0.06 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.06 | Why? |
| Air Pollutants | 2 | 2018 | 3110 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.06 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.06 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.06 | Why? |
| Communication | 1 | 2020 | 5206 | 0.06 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
| Risk | 3 | 2019 | 5288 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Cholesterol, LDL | 2 | 2017 | 499 | 0.06 | Why? |
| Delivery of Health Care | 2 | 2019 | 15909 | 0.06 | Why? |
| Age of Onset | 1 | 2003 | 557 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.06 | Why? |
| Computational Biology | 1 | 2017 | 4514 | 0.06 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.06 | Why? |
| Registries | 1 | 2021 | 12327 | 0.06 | Why? |
| Allergy and Immunology | 1 | 2005 | 240 | 0.06 | Why? |
| Forced Expiratory Volume | 1 | 2004 | 632 | 0.05 | Why? |
| T-Lymphocytes | 2 | 1998 | 6670 | 0.05 | Why? |
| Aerosols | 1 | 2017 | 5393 | 0.05 | Why? |
| City Planning | 1 | 2020 | 53 | 0.05 | Why? |
| Population Dynamics | 1 | 2004 | 378 | 0.05 | Why? |
| Statistics, Nonparametric | 1 | 2004 | 1008 | 0.05 | Why? |
| Haploidy | 1 | 2019 | 6 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 8811 | 0.05 | Why? |
| Primary Health Care | 1 | 2019 | 4839 | 0.05 | Why? |
| Animals | 10 | 2019 | 78931 | 0.05 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.05 | Why? |
| Mites | 1 | 2019 | 26 | 0.05 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.05 | Why? |
| Drugs, Essential | 1 | 2001 | 117 | 0.05 | Why? |
| Bronchial Provocation Tests | 1 | 1998 | 20 | 0.05 | Why? |
| Gene Frequency | 1 | 2004 | 1210 | 0.05 | Why? |
| Olfaction Disorders | 1 | 2018 | 3704 | 0.05 | Why? |
| Public Policy | 2 | 2020 | 1894 | 0.05 | Why? |
| Phenol | 1 | 2018 | 24 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.05 | Why? |
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2019 | 38 | 0.05 | Why? |
| Droughts | 1 | 2018 | 30 | 0.05 | Why? |
| Case-Control Studies | 4 | 2019 | 17671 | 0.04 | Why? |
| Health Surveys | 2 | 2014 | 2841 | 0.04 | Why? |
| Comparative Genomic Hybridization | 1 | 2017 | 33 | 0.04 | Why? |
| Drug Implants | 1 | 2017 | 43 | 0.04 | Why? |
| Basophils | 1 | 1998 | 179 | 0.04 | Why? |
| Information Technology | 1 | 2021 | 278 | 0.04 | Why? |
| Geography | 1 | 2004 | 1801 | 0.04 | Why? |
| Conjunctivitis, Allergic | 1 | 2019 | 94 | 0.04 | Why? |
| Polyploidy | 1 | 1997 | 16 | 0.04 | Why? |
| Drug Administration Routes | 1 | 2017 | 106 | 0.04 | Why? |
| Biomechanical Phenomena | 1 | 2018 | 291 | 0.04 | Why? |
| Bacterial Infections | 1 | 2010 | 2229 | 0.04 | Why? |
| Infant, Newborn | 4 | 2019 | 23105 | 0.04 | Why? |
| Polyethylene Glycols | 1 | 2021 | 574 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Adaptation, Biological | 1 | 2017 | 179 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Dilatation | 1 | 2017 | 181 | 0.04 | Why? |
| Treatment Outcome | 3 | 2017 | 51732 | 0.04 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.04 | Why? |
| Genome, Human | 1 | 2019 | 400 | 0.04 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Quebec | 1 | 2017 | 498 | 0.04 | Why? |
| ROC Curve | 2 | 2018 | 6024 | 0.04 | Why? |
| Carotid Arteries | 1 | 2017 | 182 | 0.04 | Why? |
| Surgery, Computer-Assisted | 1 | 2017 | 183 | 0.04 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.04 | Why? |
| Quantitative Trait Loci | 1 | 2017 | 340 | 0.04 | Why? |
| Infant | 4 | 2019 | 30274 | 0.04 | Why? |
| Maternal Exposure | 1 | 2017 | 173 | 0.04 | Why? |
| Adiposity | 1 | 2018 | 329 | 0.04 | Why? |
| Adaptation, Physiological | 1 | 2018 | 359 | 0.04 | Why? |
| Finland | 1 | 2017 | 671 | 0.03 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.03 | Why? |
| Cyprus | 1 | 2014 | 186 | 0.03 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.03 | Why? |
| Dermatitis, Atopic | 2 | 2019 | 714 | 0.03 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.03 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 552 | 0.03 | Why? |
| Physician-Patient Relations | 1 | 2003 | 1266 | 0.03 | Why? |
| Public Health Practice | 1 | 2001 | 945 | 0.03 | Why? |
| Smoking Cessation | 1 | 2001 | 826 | 0.03 | Why? |
| Virus Diseases | 1 | 2010 | 3779 | 0.03 | Why? |
| Belgium | 1 | 2019 | 2064 | 0.03 | Why? |
| Health Priorities | 1 | 2001 | 959 | 0.03 | Why? |
| Species Specificity | 1 | 1997 | 1356 | 0.03 | Why? |
| Latin America | 1 | 2018 | 1721 | 0.03 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.03 | Why? |
| North America | 1 | 1997 | 1400 | 0.03 | Why? |
| Immune Tolerance | 1 | 2017 | 608 | 0.03 | Why? |
| Climate Change | 1 | 2020 | 901 | 0.03 | Why? |
| DNA | 1 | 2018 | 778 | 0.03 | Why? |
| Antibody Specificity | 1 | 2017 | 1328 | 0.03 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.03 | Why? |
| Cats | 1 | 1998 | 1890 | 0.03 | Why? |
| Reference Values | 1 | 2014 | 795 | 0.03 | Why? |
| Pregnancy | 4 | 2019 | 23879 | 0.03 | Why? |
| Molecular Sequence Data | 1 | 1997 | 3198 | 0.03 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.03 | Why? |
| Occupations | 1 | 2017 | 733 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.03 | Why? |
| Health Services | 1 | 2017 | 765 | 0.03 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.03 | Why? |
| Program Development | 1 | 2017 | 1089 | 0.03 | Why? |
| Disabled Persons | 1 | 2001 | 1152 | 0.03 | Why? |
| Program Evaluation | 1 | 2019 | 1929 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Cough | 1 | 2004 | 4891 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.02 | Why? |
| Curriculum | 1 | 2003 | 3083 | 0.02 | Why? |
| Asia | 1 | 1997 | 2399 | 0.02 | Why? |
| Respiratory Tract Infections | 1 | 2010 | 6817 | 0.02 | Why? |
| Poverty | 1 | 2001 | 2302 | 0.02 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.02 | Why? |
| Polymorphism, Genetic | 1 | 1997 | 1074 | 0.02 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 1998 | 3776 | 0.02 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.02 | Why? |
| Sex Characteristics | 1 | 2017 | 1120 | 0.02 | Why? |
| Base Sequence | 1 | 1997 | 3581 | 0.02 | Why? |
| Patient Compliance | 1 | 2019 | 1468 | 0.02 | Why? |
| Interferon-gamma | 1 | 1998 | 2711 | 0.02 | Why? |
| Smell | 1 | 2018 | 1851 | 0.02 | Why? |
| Temperature | 1 | 2018 | 2305 | 0.02 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.02 | Why? |
| Lipids | 1 | 2014 | 1079 | 0.02 | Why? |
| Adjuvants, Immunologic | 1 | 2017 | 1709 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Tomography, X-Ray Computed | 1 | 1994 | 25144 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.02 | Why? |
| Education, Medical | 1 | 2003 | 2461 | 0.02 | Why? |
| Health Care Rationing | 1 | 2001 | 2558 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.02 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.02 | Why? |
| Wounds and Injuries | 1 | 2019 | 1708 | 0.02 | Why? |
| Palliative Care | 1 | 2020 | 2665 | 0.02 | Why? |
| Parents | 1 | 2019 | 2758 | 0.02 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 1994 | 1383 | 0.02 | Why? |
| Radioallergosorbent Test | 1 | 1984 | 4 | 0.02 | Why? |
| Lung | 1 | 1994 | 31049 | 0.02 | Why? |
| Cities | 1 | 2017 | 4937 | 0.02 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.02 | Why? |
| Clinical Competence | 1 | 2019 | 3263 | 0.02 | Why? |
| Fear | 1 | 2019 | 3607 | 0.02 | Why? |
| Advisory Committees | 1 | 2010 | 1418 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.01 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.01 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Health Policy | 1 | 2001 | 6242 | 0.01 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.01 | Why? |
| Epithelium | 2 | 1993 | 330 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Models, Statistical | 1 | 2017 | 5312 | 0.01 | Why? |
| Spain | 1 | 2018 | 15545 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Acute Disease | 1 | 2010 | 6029 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Dermatitis, Contact | 1 | 1978 | 98 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Busulfan | 1 | 1975 | 22 | 0.01 | Why? |
| Abnormalities, Drug-Induced | 1 | 1975 | 72 | 0.01 | Why? |
| Calcimycin | 1 | 1993 | 6 | 0.01 | Why? |
| Hydroxyeicosatetraenoic Acids | 1 | 1993 | 5 | 0.01 | Why? |
| Ovary | 1 | 1975 | 133 | 0.01 | Why? |
| Fiber Optic Technology | 1 | 1993 | 71 | 0.01 | Why? |
| Fibronectins | 1 | 1993 | 92 | 0.01 | Why? |
| Albuterol | 1 | 1993 | 105 | 0.01 | Why? |
| Dinoprostone | 1 | 1993 | 101 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| China | 1 | 2017 | 50654 | 0.01 | Why? |
| Cell Survival | 1 | 1993 | 1581 | 0.01 | Why? |
| Stress, Psychological | 1 | 2010 | 10231 | 0.01 | Why? |
| Immunity, Cellular | 1 | 1978 | 3614 | 0.00 | Why? |
| Bronchoscopy | 1 | 1993 | 991 | 0.00 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 2309 | 0.00 | Why? |
| Epithelial Cells | 1 | 1993 | 3508 | 0.00 | Why? |
| Rosette Formation | 1 | 1978 | 2 | 0.00 | Why? |
| In Vitro Techniques | 1 | 1978 | 1027 | 0.00 | Why? |
| Gonadal Steroid Hormones | 1 | 1975 | 328 | 0.00 | Why? |
| Endoplasmic Reticulum | 1 | 1975 | 430 | 0.00 | Why? |
| Rats | 1 | 1975 | 2764 | 0.00 | Why? |
| B-Lymphocytes | 1 | 1978 | 4418 | 0.00 | Why? |